RANKL (Receptor Activator of Nuclear Factor Kappa-B Ligand), also known as TNFSF11 or TRANCE, is a cytokine that belongs to the tumor necrosis factor superfamily. It plays essential roles in bone metabolism, immune system regulation, and has been implicated in neuroinflammatory processes underlying neurodegenerative diseases.
| Property | Value |
|----------|-------|
| **Gene Symbol** | RANKL (TNFSF11) |
| **Full Name** | Tumor Necrosis Factor Ligand Superfamily Member 11 |
| **Chromosomal Location** | 13q14 |
| **NCBI Gene ID** | 9600 |
| **OMIM** | 602642 |
| **Ensembl** | ENSG00000120659 |
| **UniProt** | O14788 |
| **Associated Diseases** | Osteoporosis, rheumatoid arthritis, bone metastasis, neuroinflammation |
RANKL is a human gene whose product rANKL is a type II transmembrane protein that can exist in both membrane-bound and soluble forms. It functions as the primary regulator of osteoclastogenesis and modulates immune responses:. Variants in RANKL have been implicated in Neurodegeneration, Musculoskeletal, Cancer. This page covers the gene's normal function, disease associations, expression patterns, and key research findings relevant to neurodegeneration.
RANKL is a type II transmembrane protein that can exist in both membrane-bound and soluble forms. It functions as the primary regulator of osteoclastogenesis and modulates immune responses:
- Osteoclast Formation: RANKL binds to RANK on osteoclast precursors, triggering the NF-κB, c-Fos, and NFATc1 signaling cascades that drive differentiation into mature osteoclasts
- Bone Remodeling: The RANKL/OPG ratio determines bone resorption rates
- Pathological Bone Loss: Elevated RANKL contributes to conditions like osteoporosis and rheumatoid arthritis
- T Cell Co-stimulation: RANKL provides critical co-stimulatory signals for T cell activation and survival
- Dendritic Cell Function: Promotes dendritic cell survival and migration
- Lymphoid Organogenesis: Essential for formation of lymph nodes and medullary thymic epithelial cells
- Microglial Activation: Soluble RANKL can activate microglia, promoting production of pro-inflammatory cytokines
- Synaptic Plasticity: Emerging evidence suggests RANKL may modulate synaptic function
- Blood-Brain Barrier: RANKL may influence BBB permeability during inflammation
- Alzheimer's Disease: Elevated RANKL levels in CSF and brain tissue correlate with disease progression. RANKL promotes microglial activation and neuroinflammation
- Parkinson's Disease: RANKL may contribute to dopaminergic neuron loss through neuroinflammation
- Multiple Sclerosis: RANKL drives inflammatory bone erosion and CNS demyelination
- ALS: Altered RANKL signaling observed in ALS patients
- Osteoporosis: High RANKL/OPG ratio leads to excessive bone resorption
- Rheumatoid Arthritis: Synovial fibroblasts produce RANKL, driving bone erosion
- Bone Metastases: Tumor cells often express RANKL to promote osteolysis and metastasis
- Multiple Myeloma: Malignant plasma cells hijack RANKL for survival
RANKL is expressed in various tissues:
- High Expression: Lymph nodes, thymus, bone marrow, spleen
- Moderate Expression: Heart, skeletal muscle, brain
- Cellular Sources: Activated T cells, B cells, osteoblasts, fibroblasts, endothelial cells
In the brain, RANKL is produced by neurons and glia, with increased expression during neuroinflammation.
- Denosumab: Monoclonal antibody against RANKL, approved for osteoporosis and bone metastases
- OPG-Fc: Recombinant osteoprotegerin as decoy receptor
- Blocking RANKL to reduce neuroinflammation in AD/PD
- Understanding RANKL's role in synaptic dysfunction
- Targeting RANKL in microglia for neuroprotection